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Glioblastoma (GBM) is a prototypical heterogeneous brain tumor refractory to conventional therapy. A small residual
population of cells escapes surgery and chemoradiation, resulting in a typically fatal tumor recurrence ~7 mo after
diagnosis. Understanding themolecular architecture of this residual population is critical for the development of successful
therapies. We used whole-genome sequencing and whole-exome sequencing of multiple sectors from primary and paired
recurrent GBM tumors to reconstruct the genomic profile of residual, therapy resistant tumor initiating cells. We found
that genetic alteration of the p53 pathway is a primarymolecular event predictive of a high number of subclonal mutations
in glioblastoma. The genomic road leading to recurrence is highly idiosyncratic but can be broadly classified into linear
recurrences that share extensive genetic similarity with the primary tumor and can be directly traced to one of its specific
sectors, and divergent recurrences that share few genetic alterations with the primary tumor and originate from cells that
branched off early during tumorigenesis. Our study provides mechanistic insights into how genetic alterations in primary
tumors impact the ensuing evolution of tumor cells and the emergence of subclonal heterogeneity.
[Supplemental material is available for this article.]
The presence of multiple cancer cell clones within a single tumor has
been explained as a Darwinian process in which different clones
compete for limited resources, and the most phenotypically fit cells
eventually prevail (Greaves and Maley 2012; Yates and Campbell
2012; Aparicio and Caldas 2013). It has been suggested that such
heterogeneity allows a tumor to respond to local and systemic selec-
tive pressures, such as those exerted by therapeutic interventions
(Nowak and Sigmund 2004; Greaves and Maley 2012; Bozic et al.
2013). For example, the presence of subclonal driver mutations in
cancer cells was indicative of rapid disease progression in chronic
lymphocytic leukemia (Landau et al. 2013). Using single-cell se-
quencing or massively parallel sequencing, clonal architectures
ranging from complex polyclonal structures to monoclonal tumors
have been described in cancer lineages such as those of the breast,
kidney, andblood (Navin et al. 2011;Dinget al. 2012; Shahet al. 2012;
Landauet al. 2013;Gerlinger et al. 2014).Distinct subclonal tumorcell
populations relating to mosaic amplification of receptor tyrosine ki-
nases were reported in glioblastoma (GBM), suggesting a similarly
dynamic architecture for this disease (Snuderl et al. 2011; Nickel et al.
2012; Szerlip et al. 2012; Sottoriva et al. 2013).
GBM is the most common malignant brain tumor in adults
(Van Meir et al. 2010; Dunn et al. 2012) and is standardly treated
with surgical resection followed by concomitant radiotherapy and
administration of the alkylating agent temozolomide (TMZ) (Stupp
et al. 2005). Despite this aggressive treatment regimen, themedian time
 2015 Kim et al. This article is distributed exclusively by Cold Spring Harbor
Laboratory Press for the first six months after the full-issue publication date (see
http://genome.cshlp.org/site/misc/terms.xhtml). After six months, it is avail-
able under a Creative Commons License (Attribution-NonCommercial 4.0 In-
ternational), as described at http://creativecommons.org/licenses/by-nc/4.0/.
12These authors contributed equally to this work.
Corresponding author: rverhaak@mdanderson.org
Article published online before print. Article, supplemental material, and pub-
lication date are at http://www.genome.org/cgi/doi/10.1101/gr.180612.114.
25:000–000 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/15; www.genome.org Genome Research 1
www.genome.org
 Cold Spring Harbor Laboratory Press on February 11, 2015 - Published by genome.cshlp.orgDownloaded from 
to disease recurrence is 6.9mo, with >90% of GBM tumors recurring at
theoriginal site (WenandKesari 2008). Therapy targeting theepidermal
growth factor receptor variant III (EGFRvIII) led to an improved overall
survival time among patients with GBM; however, 82% of these pa-
tients lost EGFRvIII expression when the tumor recurred, which
suggests a competitive advantage for non-EGFRvIII expressing
clones in these tumors (Sampson et al. 2010). Achieving a better
understanding of the clonal structure of cancer cells is thus of vital
importance and may inform the development of additional tar-
geted therapies for rapidly lethal forms of cancer, such as GBM.
Here, we analyzed genomic profiles of 252GBM samples from
The Cancer Genome Atlas (TCGA) (Brennan et al. 2013), and 60
biopsies taken from 23 pairs of pre- and post-treatment GBMs, to
understand (1) the intratumoral clonal compositions of primary
GBM; and (2) howGBM responds to therapeutic intervention. Our
results provide a molecular portrait of GBM recurrence.
Results
Sample characteristics and mutation calling
In this study, we performed an analysis of genomic data from 252
untreated GBM samples from The Cancer Genome Atlas (cohort I).
To study tumor responses to treatment, we obtained a second cohort
of tumor samples, for which we collected pairs of primary and first
recurrent GBM samples from 21 patients and added pairs of sec-
ondaryGBM andnext disease occurrence samples from two patients
(cohort II). Prior to disease recurrence, 21 patients in cohort II had
received radiotherapy, and 17 of them had also received adjuvant
TMZ. A variety of treatments, including carmustine and anti-in-
flammatory agents, were administered to the remaining patients in
cohort II. An IDH1 R132 mutation was detected in two cases. The
clinical data for cohort II is summarized in Supplemental Table 1.
Integrative analysis identifies clonal and subclonal mutations
To investigate the clonal architecture of GBM, we classified somatic
mutations into clonal and subclonal categories by integrating variant
allele fraction, DNA copy number, genotype, and tumor purity
(Methods). We used PyClone, a Bayesian clustering method that si-
multaneously estimates the distribution of the cellular frequency for
each mutation (Roth et al. 2014). After correcting for tumor cell
content, the cellular frequency of each mutation was used to infer
themutation clonality. By definition, clonalmutations occur early in
or beforemalignant transformation and thus are present in all tumor
cells. In contrast, subclonal mutations occur later in tumor expan-
sion and are present in only a subset of tumor cells. Of 17,636 so-
matic single nucleotide variations (sSNVs) detected in cohort I
(Brennan et al. 2013), we found 67.9% to be clonal (n = 11,973,
median across samples; 68.3%6 19.3%) and 29.8% (n = 5249) to be
subclonal. A minor fraction of mutations could not be classified
(2.3%). To validate our classification approach, we presumed that
clonal mutations were present in all tumor compartments and thus
should be spatially ubiquitous. We sequenced the exomes of two
nonoverlapping sectors from 13 tumors in cohort II, classified
detectedmutations as clonal or subclonal, and compared both types
of sSNVs with spatial distribution. The percentage of ubiquitous
mutations (present in both tumor sectors) per sample ranged from
43.1% to 74.7% (59.3.5% 6 10%) (Supplemental Fig. 1A), and the
majority of ubiquitousmutations (85.6%)were classified as clonal. In
contrast, 41.2% of the private mutations were classified as clonal
(Fig. 1A; Supplemental Table 2), which was a significant difference
(P = 2.23 1016, x2 test). In a single recurrent tumor sample that had
three biopsies available, we found a similar percentage of ubiquitous
mutations (45.3%) (Supplemental Fig. 1B). Separating patients into
discrete age groups by intervals of 10 yr, we found a significant linear
correlation between clonal mutations and age (P = 3.69 3 107,
multiple group analysis of variance) (Fig. 1B), suggesting that the
majority of clonal mutations were acquired before gliomagenesis
and accumulated over the life span of the patient at time of diag-
nosis. This observation was corroborated by the dominant presence
of C > T transitions, reminiscent of germline substitutions, in the
clonal mutation spectrum (Supplemental Fig. 2A; Nik-Zainal et al.
2012; Alexandrov et al. 2013; Tomasetti et al. 2013). We did not
observe a correlationbetweenage and subclonalmutations (P= 0.62).
We evaluated the clonal status of significantly mutated GBM genes
and recurrent cancer genes from the cancer gene census (nonsilent
mutation frequency greater than three in the cohort) (Supplemental
Fig. 2B). Very few genes were entirely clonal or subclonal (Andor et al.
2014). However, the majority (90.5%) of TP53 and PIK3CA/PIK3R1
mutations were clonal, suggesting a founder role for these events in
GBM. In contrast, receptor tyrosine kinases such as EGFR, PDGFRA,
and AKT pathway regulator PTEN were more evenly distributed
Figure 1. Inference of mutational clonality and association with patient age. (A) Validation of clonal and subclonal classifications using multisector se-
quencing.Mutations found in all nonoverlapping tumor sectors from the same tumor were defined as ubiquitous mutations, otherwise as private. Ubiquitous
and private mutations were further subdivided into clonal and subclonal mutations, resulting in four categories (ubiquitous/clonal, ubiquitous/subclonal,
private/clonal, and private/subclonal). (B) The clonal mutation frequency correlates with age across 221 primary GBMs with available age information (left
panel), whereas the subclonal mutation frequency does not (right panel). The patients were separated into discrete age groups by intervals of 10 yr.
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between the clonal and subclonal mutation groups across cohort I,
suggesting heterogeneous deregulation timing.
Subclonal mutations are associated with p53 pathway
alterations
To identify genetic aberrations that are associated with subclonal
progression, we juxtaposed somatic mutations, DNA copy number
alterations, and clonal compositions in cohort I. Interestingly, de-
regulation of the p53 pathway, inparticularTP53 somaticmutations
(n = 78) andMDM2 amplifications (n = 21), was strongly associated
with an increased fraction of subclonal mutations (P = 6 3 105,
Wilcoxon rank-sum test) (Fig. 2A), and this association was
independent of age (Methods). G-CIMP positive tumors, a subclass
of GBM characterized by a hypermethylator phenotype, mutations
in isocitrate dehydrogenase I (IDH1), and mutations in TP53
(Noushmehr et al. 2010), accordingly showed a high proportion of
subclonal mutations. Since subclonal mutations were associated
with unfavorable outcome in chronic lymphocytic leukemia
(Landau et al. 2013), we compared the event-free survival of patients
represented in our data set whose primary tumor had a dominance
of clonalmutations to patients with tumors in which high fractions
of subclonal mutations were detected. Interestingly, the subclonal
tumor group showed significantly longer event-free survival than
the clonal tumor group (P = 0.025, log-rank test), but only when
limiting the analysis to patients younger than 55 yr of age at time of
diagnosis (Fig. 2B; Supplemental Fig. 3). TP53mutation status alone
did not correlate with outcome (data not shown). The increased
fraction of subclonal mutations in GBM harboring p53 pathway
alterations may be indicative of an elevated tolerance to DNA
damage or apoptosis suppression (Offer et al. 2002; Kojima et al.
2005; Pant et al. 2013).
p53 pathway status affects mutational burden in recurrent
tumor
To further examine the effect of TP53 mutations on tumor evolu-
tion, we performed exome sequencing and DNA copy number
analysis on 23 pairs of first GBM andmatched recurrent tumors in
cohort II. In line with a recent report (Johnson et al. 2014), we
found that the majority of primary GBM mutations could also be
detected in the tumor after disease relapse (median overlap 67%;
range 18%–85%) (Supplemental Table 3). Five recurrent tumors
showed a very high number of clonal and/or subclonal sSNVs and
were considered hypermutated (12–131 mutations per Mb). De-
spite the high overall population frequency of genetic alterations
in TP53 (27.9%), EGFR (57.4%), and CDKN2A (57.8%) (Brennan
et al. 2013), copy number alterations and sSNVs in these and other
GBM driver genes were frequently present at time of diagnosis but
absent in the tumor recurrence, mutated at a difference base, or
deleted/amplified with different copy number breakpoints (Fig.
3A). It is therefore unlikely that any of these genes can be un-
ambiguously flagged as an initiating mutation of IDH1 wild-type
glioblastoma, and their frequent alterations can be best explained
by intratumoral evolutionary pressures resulting in convergent
evolutionary events. For example, we observed focal amplification
of the Rb pathway regulator CDK4 in three primary GBM tumors
but not in two of the three corresponding recurrent tumors (Fig.
3A). Interestingly, both cases had acquired a homozygous deletion
of upstream Rb pathway regulator CDKN2A, suggesting a com-
pensatory effect to maintain the deregulation of the Rb pathway.
We speculate that one common pathway of tumor initiation starts
with loss of 10q and gain of Chromosome 7, which predispose to
deactivation of PTEN and activating mutations/amplifications in
major oncogenes.
Mutations in TP53were detected in seven primaryGBMs, and
in two cases, the DNA binding domain mutation was no longer
detected in the recurrent tumor (mutant locus coverage 2793 and
463 in the respective recurrent samples). In one case, the original
TP53 mutation was replaced with a different variant. One re-
current tumor acquired a TP53mutation that was not found in the
matching primary, an observation confirmed by ultradeep se-
quencing of the diagnostic tumor sample (average mutant locus
coverage 11003) (Supplemental Fig. 4). We compared the muta-
tion frequencies (mutations per megabase, adjusted for coverage)
at diagnosis and after disease relapse, and found disparate muta-
genesis trends between TP53 mutant tumors and TP53 wild-type
tumors (Fig. 3B). When compared to thematching primary tumor,
TP53 mutant recurrent GBM showed an increase in subclonal
mutation frequency, whereas GBM with wild-type TP53 did not,
and the difference was statistically significant (P = 0.0015;
Wilcoxon rank-sum test) (Fig. 3C). The clonalmutation frequency
was unaffected (P = 0.23;Wilcoxon rank-sum test). Tumor purity,
estimated by allele-specific copy number analysis of tumors
(ASCAT) (Van Loo et al. 2010), did not confound the results
(Supplemental Fig. 5). This increase in subclonal mutation fre-
quency in TP53 mutant but not TP53 wild-type tumors after
disease relapse further exposed the association between TP53
mutation and subclonal tumor progression.
Whole-genome sequencing inferred tumor evolution
To comprehensively cover GBM tumor heterogeneity and disease
progression, we performed whole-genome sequencing on 10 pri-
mary-recurrence pairs from cohort II (Supplemental Table 1). We
identified a median number of 4224 mutations (range from 2063
to;142,984) in the genome-wide sequencing data from20 tumors
(Supplemental Table 4). One recurrent tumor had an extremely
high number (142,984) of mutations, and this sample was among
the five recurrent tumors with hypermutated exomes (Fig. 3A).
We utilized the large number of mutations detected in each
tumor to investigate the architecture of disease evolution by ana-
lyzing the distribution of purity-scaled variant allele fractions (PS-
VAFs) determined using the SciClone method (Miller et al. 2014).
SciClone is a variational Bayesian algorithm to infer genetic com-
position of subclones from the variant allele frequencies of somatic
mutations. To avoid potential confounding effects fromDNAdosage,
loss of heterozygosity (LOH), and sequencing depth, we limited the
analysis tomutationswith at least 603 coverage and located in copy-
neutral and LOH-free regions. Theoretically, heterozygousmutations
with 0.5 PS-VAF are clonal mutations present in all tumor cells.
Analysis of PS-VAFs frompaired primary and recurrent tumors
revealed at least two evident patterns ofGBM relapse. The ancestral
cell of origin pattern was demonstrated by cases TCGA-06-0152
(Fig. 4A) and TCGA-14-1034 (Supplemental Fig. 6A). In this pat-
tern, primary and recurrent tumors shared a cluster of clonal mu-
tations close to PS-VAF 0.5; whereas at the same time, a large cluster
of clonal mutations in the primary tumor disappeared in the
matching recurrent tumor. The limited overlap of clonalmutations
implicated a common ancestral cell that gave rise to both primary
and recurrent tumors. The lack in overlapping subclonal muta-
tions and the wide range of PS-VAFs from 0 to 0.5 in primary and
recurrent specific mutations suggested that the two subsequent
disease instances evolved independently (Fig. 5A).
Adifferent patternwas observed in cases TCGA-06-0125 (Fig. 4B),
TCGA-06-0190, TCGA-06-0221, and TCGA-14-1402 (Supplemental
Glioblastoma disease evolution
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Figure 3. Spectrum of somatic mutations in primary and recurrent GBM. (A) The number of mutations detected in exome sequencing (top panel), clinical
characteristics (second panel), EGFRvIII aberrations (third panel), copy number alterations (fourth panel), and somatic exonic mutations (bottom panel). Only
frequently amplified, deleted, andmutatedGBMgenes are included in the copy number andmutation panels.v (mutation of a different nucleotide in the same
gene); V (DNA copy number alteration defined by different breakpoints). Clonal status for one sample with an extreme number of mutations could not be
reliably classified and is shown in gray. (B) Comparison of subclonal (leftpanel) and clonal (rightpanel)mutation frequencies betweenprimary or secondaryGBM
and matching recurrent tumors. Patients treated with TMZ are indicated with a brown triangle. (C ) Association of TP53 mutation with subclonal mutational
burden. Changes in clonal (left panel) and subclonal (right panel)mutation frequency are indicated as yellow dots for GBMharboringwild-type TP53 and purple
triangles for tumors withmutated TP53 in both primary and recurrent tumors. The green diamond represents a patient who acquired a TP53mutation at GBM
recurrence; the blue diamond represents a case where a TP53 mutation was observed in the primary but not the matching tumor recurrence. A P-value was
obtained by performing a Wilcoxon rank-sum test comparing subclonal mutation frequency change between TP53 wild-type and mutant groups.
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Figure 4. Comprehensive comparison of mutations in four pairs of primary and recurrent GBM. Each row in the upper panels of A–D represents exonic
mutations detected in sectors of the primary tumor (P.1, P.2) and exonic mutations detected in sectors of the matching recurrent GBM (R.1, R.2, R.3).
Mutations are color-coded for cancer cell fractions (tumor purity-corrected cellular frequencies), in which a cancer cell fraction of 1.0 indicates that
amutation was present in all tumor cells. The columns represent the same chromosomal nucleotide position in all samples displayed. The bottom panels of
A–D show scatter plots of the copy-neutral and non-LOH localizing mutations detected in whole-genome sequencing data of the primary and recurrent
tumor. The x-axis and y-axis indicate purity-scaled variant allele fractions. Variant allele frequency distribution plots for individual tumors are also displayed
at the bottom for primary tumor and at the right side for its matching recurrent tumor.
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Fig. 6B,C,D). In these samples, a high degree of overlap between clonal
mutations in the primary and the recurrent tumor was observed, as
well as a general absence of primary-specific clonal mutations, which
would argue against the evolution of the recurrent tumor from an
ancestral cell. For these cases, it appearedmore likely that the recurrent
tumors developed from the residual primary disease, and specific
subclones were retained and subsequently expanded at tumor relapse.
Wenote that this residual-based recurrencewas dynamic. For instance,
in the case TCGA-06-0221 (Supplemental Fig. 6C), a primary subclone
at 0.1 PS-VAF underwent clonal expansion, resulting in a cluster of
mutations at 0.5 PS-VAF in the relapse (Fig. 5B).
Two cases, TCGA-06-0210 and TCGA-06-0211, could not be
classified into eithermodel (Fig. 4C,D). The presence and expansion of
subclonal mutations of the primary tumors at recurrence suggested
residual disease development, but the presence of clonal primary-only
mutations suggested theancestral cellmodel.We speculate that the two
modelsmightbothbeoperating simultaneously in these tumors. In the
remaining two pairs, either the primary tumor (TCGA-19-1389) or the
recurrent tumor (TCGA-06-0171) was found to be monoclonal, which
coincided with predicted tumor purity levels of 0.31 and 0.2, re-
spectively; andwe expect that the relative lack of tumor cells interfered
with prediction of evolutionary patterns (Supplemental Fig. 6E,F).
To address the possibility that the
lack of overlap between subsequent tu-
mors and subclones was due to intra-
tumoral heterogeneity, we analyzed
exome sequencing data from a second,
and in one case a third, sector of seven
primary and six recurrent cohort II tu-
mors. On average, 20 additional exonic
mutations were detected in the second
primary tumor biopsy, which repre-
sented a 25% increase on the total
number of mutations found in the pri-
mary tumor. However, the additionally
recovered mutations were in majority
unique to the second primary sample
(median: 17 of 20) and not detected in
the tumor recurrence (Supplemental Ta-
ble 5). Analysis of a second recurrent
tumor biopsy did not alter this result but
confirmed that the majority of ‘‘second
biopsy’’ mutations were not conserved
between time points. We therefore sug-
gest that intratumoral heterogeneity did
not explain the large number of muta-
tions that were uniquely detected in
primary and recurrence.
Evolutionary phylogenetic trees con-
structed from exome mutation profiles
showed that primary and recurrent tumor
sectors grouped in separate branches, with
varying separation structures (Fig. 6). In
one sample, TCGA-06-0125, the tree sug-
gested that the tumor cells seeding the re-
current tumor were derived from primary
tumor sector 2, which is consistent with
the observations made in our analysis of
the whole-genome sequencing data. Simi-
larly, in TCGA-06-0211, the structure sug-
gested that the tumor cells responsible for
disease relapse were predominantly found
in sector 1, where sectors 2 and 3 branched off linearly at a later time
point.
Therapy-induced hypermutation is a subclonal process
We observed temozolomide treatment induced hypermutation,
previously described in secondary GBM (Hunter et al. 2006;
Johnson et al. 2014), in the recurrent tumor of five patients. The
majority of mutations were classified as subclonal, and this was
confirmed by the analysis of two independently sequenced bi-
opsies from one hypermutated recurrent tumor, in which we
observed 2429 and 5980 somatic point mutations, respectively,
but only 163 shared mutations between the two biopsies (Sup-
plemental Table 2). Multiple DNA mismatch repair genes, in-
cludingMSH2,MSH6,MLH1,MLH3, and POLD3, were found to be
mutated in this specific tumor; however, none was shared by the
two independently sequenced biopsies, suggesting that mecha-
nisms not related to these genes and resulting in hypermutation
could exist. Although the number of samples was too small to
identify genes associated with hypermutator phenotype at sta-
tistical significance, we noted that the receptor tyrosine kinases
EGFR and ALK were among the eight genes mutated in all six
Figure 5. Schematic illustration of the patterns of tumor recurrence. (A) In the ancestral cell origin
model, therapeutic interventions removed all dominant disease clones from the primary tumor but not
refractory ancestral cells. The ancestral cell accumulates new mutations and proliferates to become the
recurrent tumor. In this model, mutations shared by primary and recurrent tumors were presumably
only from the ancestral cell, and the two subsequent tumors were thus more divergent. (B) In the clonal
evolution model, the treatment removed most of the primary tumor cells, but cells from the major
primary disease clones survived and continued to grow to result in a recurrent tumor. During this
process, additional mutations were accumulated and therefore detected in the recurrent tumor, and all
primary tumor clonal mutations are retained in the recurrence.
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hypermutator samples (Supplemental Table 6). MGMT was
methylated in all five primary tumors and in three of the five
recurrent tumors, whereas MGMT status was not available for the
remaining three recurrent tumors.
Following their second surgery to remove a GBM tumor, the
five patients had respective lengths of survival of 35, 64, 107, 191,
and 245 d, relative to a median survival of approximately 8 mo
after surgery upon disease progression (Wen and Kesari 2008). The
clinical outcome of the hypermutators illustrated the lethality of
GBM, but the limited number of cases is unable to confirm that
a high level of mutation is associated with relatively aggressive
disease progression at statistically significant levels.
Discussion
As indicated by the adjective ‘‘multiforme,’’ the histopathological
features of glioblastoma show a high degree of intratumor het-
erogeneity. Genomic studies have further illustrated this disease
characteristic by demonstrating local variation in the amplifica-
tion patterns of receptor tyrosine kinases (Snuderl et al. 2011;
Szerlip et al. 2012; Sottoriva et al. 2013; Francis et al. 2014) as well
as a wide landscape of somatic alterations, expression subtypes,
and epigenetic differences across GBM (Noushmehr et al. 2010;
Verhaak et al. 2010; Brennan et al. 2013; Zheng et al. 2013). Here,
we expand our knowledge of GBM by evaluating heterogeneity
in a large number of primary tumor samples from TCGA as well
as through a comparison of pre- and post-treatment GBM tumor
pairs.
We developed a computational approach to infer the cellular
frequency of sSNVs and to classify mutations as clonal or subclonal,
which we then validated using multisector sequencing (Gerlinger
et al. 2012). Corroborating the findings from previous reports (Nik-
Zainal et al. 2012; Alexandrov et al. 2013; Tomasetti et al. 2013), we
note that the number of clonal but not subclonal mutations found
at the time of diagnosis increased with the age of the patient, and
that clonal mutations reflected the signature of germline sub-
stitutions. Over the lifetime of the patient, the cancer cell of origin
may thus have been subjected to mutational processes before ac-
quiring the necessary alterations to become tumorigenic, and this
observation could be used to increase the specificity of algorithms
aimed at identifying cancer-contributory genes (Lawrence et al.
2013). Mutation of TP53 has been related to an increased frequency
of double-strand breaks and chromothripsis in medulloblastoma
(Rausch et al. 2012) and tumor progression from low-grade to high-
grade glioma (Ishii et al. 1999; Fulci et al. 2002). We extended our
knowledge of the damaging effects of TP53 deactivation by identi-
Figure 6. Phylogenetic trees based on multisector sequencing of primary and recurrent GBM. Phylogenetic trees were constructed using mutations
from exome sequencing data of all biopsies of individual tumors. The length of branches in the tree proportionally represents the number of mutations,
and putative cancer genes are labeled.
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fying a significant correlation with increased subclonal mutation
frequency. The causality of this association could not be determined
in our analysis, but we speculate that the apoptosis-negating prop-
erties ofTP53DNAbinding domainmutations result in an increased
tolerance for acquiring and sustaining single nucleotide variants.
GBM as a cancer type is uniquely characterized by the general ab-
sence ofmetastasis and a perceived lack of self-seeding by circulating
tumor cells (Kim et al. 2009). Intratumor heterogeneity is therefore
likely dictated by local competitive advantages resulting from the
proliferationof enhanced genomic alterations, increasedvascularity,
or the morphological aspects of tumor growth such as the ability to
mix with primary tissues or expand into the ventricles (Gonzalez-
Garcıa et al. 2002). Through longitudinal comparisons of tumor
samples before and after treatment, we found that TP53-mutated
tumors showed a further increase in clonal complexity at time of
relapse, whereas TP53 wild-type recurrences appeared to have gone
through an evolutionary bottleneck, which resulted in relatively
monoclonal recurrent tumors. A high rate of complexity may pro-
vide the tumormore routes to escape therapeutic challenges, yet our
data also suggested that increased frequency of subclonal mutations
was related to a relatively favorable event-free survival. Although
further research is needed, we suggest two explanations for this
paradox. First, the longer interval between tumor occurrences may
be a reflection of a slower developing disease, which allows more
time for subclones to proliferate to detectable levels. Alternatively,
the absence of a dominant aggressive clone may indicate a reduced
rate of tumor growth as a result of the larger number of cells com-
peting for space in the cranial cavity. A number of different geneti-
cally engineered mouse models of GBM have been developed by
manipulating tumor suppressors such as Pten, Trp53, and Rb1, and it
would be of interest to evaluate whether the association between
p53 pathway alterations and subclonal tumor progression is cap-
tured in these models. Importantly, such experimental systemsmay
be used to determine whether higher levels of intratumoral hetero-
geneity are associated with decreased efficacy of targeted therapies,
which one might predict as more variety may mean more routes to
resistance. Focusing on the general patterns of disease recurrence,we
found a general instability of genomic alterations after GBM re-
currence relative to GBM primary tumor samples, which prevented
the identification of founding mutational events. The size of our
cohort II (n = 23) may not be sufficient to detect more subtle disease
pathway associations at the levels of statistical significance, and this
analysis was further complicatedby the variety of therapies provided
to the patients, ranging from the current standardof care for primary
GBM (concomitant radiotherapy and temozolomide, termed the
Stuppprotocol) (Stupp et al. 2005) to pre-2005 treatmentmodalities.
We combined whole-genome sequencing and exome se-
quencing of multiple tumor biopsies to capture the genealogy of
GBM recurrence at sufficient detail to infer the phylogeny of tumor
subclones and to trace their pattern of disease recurrence. The
existence of glioma stem cells has been a subject of much debate
and has been suggested to relate to radio- and chemotherapy re-
sistance (Bao et al. 2006), and this model may explain the patterns
of private and shared mutations observed in the two GBMs where
the recurrence appeared to have evolved from an ancestral cell
(Gilbertson and Rich 2007). In contrast, we also identified four
cases in which all clonal primary tumor mutations could be
detected in the relapse, suggesting a clonal evolution model. Fi-
nally, the exact pattern of the four remaining cases could not be
derived, suggesting either extensive intratumoral heterogeneity
and/or lack of granularity due to tumor purity.
In conclusion, this study has provided a better understanding of
intratumor heterogeneity and disease progression in GBM. Our dis-
section of the temporal sequence of mutations revealed mutational
forces acting on the cancer genome and resulted in new insights into
the patterns and dynamics of tumor evolution. Although the thera-
peutic opportunities for GBM remain limited, continuing efforts to
detail themechanisms of disease relapse will contribute to our ability
to provide curative treatment for this lethal disease.
Methods
Whole exome DNA sequencing and targeted resequencing
DNA of multisector and additional non-TCGA primary and re-
current paired tumor samples in cohort II was extracted by the
University of Texas MD Anderson Cancer Center DNA Analysis Fa-
cility following standard protocols. All specimens were obtained
from patients with appropriate consent from the relevant in-
stitutional review board. Samples were then multiplexed and se-
quenced on Illumina HiSeq 2000 by the Sequencing andMicroarray
Facility at an average target exome coverage of 1003 using 76-bp
paired-end reads. Targeted resequencing of selected mutations for
validation was performed by PCR using a microfluidic device
(FluidigmCorp.). PCR primerswith Fluidigm-compatible tails were
designed to flank the sites of interest and produce amplicons of 200
bp 6 20 bp. Oligonucleotides containing Illumina adaptor se-
quences were mixed with 20–50 ng of each DNA sample along with
a sample-specificmolecular barcode and a sequence complementary
to the primer tails. This mixture was used as the PCR template for
each sample amplified on the Fluidigm access array. PCR was per-
formedon the Fluidigmaccess array according to themanufacturer’s
instructions. Barcoded libraries were recovered for each sample in
a single collection well on the Fluidigm access array, quantified
using PicoGreen dsDNA Quantitation Reagent (Invitrogen), and
concentrations were normalized for use across libraries. Libraries
were loaded on the Illumina MiSeq instrument and sequenced
using paired-end 150-bp sequencing reads.
Whole genome DNA sequencing
Library construction and sequencing alignment (using the Human
Genome Reference Consortium build 37) were performed by the
Broad Institute as previously described (Brennan et al. 2013). All
whole-genome sequencing BAM files are available through The
Cancer Genomics Hub (https://cghub.ucsc.edu/).
Exome sequence data processing and mutation calling
Exome sequencing reads were aligned to the human reference
genome (hg19) using Burrows-Wheeler Aligner 0.7.2 (Li and
Durbin 2009). BAM files were subjected to duplication marking,
indel realignment, and recalibration using Picard version 1.7
(http://broadinstitute.github.io/picard/) and GATK version 2.4.9
(McKenna et al. 2010). On average, 70% of the bases on exonic
regions were covered with at least 20 reads of sequence. We then
applied MuTect algorithm (version 1.14) (Cibulskis et al. 2013) to
identify somatic single nucleotide variations (sSNVs) from tumor
and patient-matched normal blood samples. In this manuscript,
we limited our analysis to the mutations whose variant allele
fractions were at least 0.05. All sSNVs were annotated by ANNOVAR
(Wang et al. 2010) and Oncotator (http://www.broadinstitute.org/
oncotator). Only mutations in exon regions were included in sub-
sequent analyses. For primary samples from cohort I, sSNVs were
publically available and downloaded from the TCGA data portal
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(https://tcga-data.nci.nih.gov/docs/publications/gbm_2013/). Mu-
tation frequency was calculated by dividing the number of somatic
mutations by the number of bases that were properly covered for
mutation calling.
Validation of somatic single nucleotide variants
To validate our somatic single nucleotide mutation calls, we per-
formed targeted resequencing at high coverage (>11003). We ran-
domly selected 239 unique bases, which had been found to be mu-
tated in primary, recurrence, or both, and sequenced these in both
primary and recurrences. These sites corresponded to 367 sSNVs and
101 wild-type nucleotides. In total, 343 of 367mutations called from
the exome sequencing data were detected in the high coverage data,
resulting in a true positive validation rate of 93.5%. Evidence for a low
allelic fraction somatic mutation was observed in nine of 101 wild-
type nucleotides. The variant allelic fractions (VAFs), i.e., the number
of reads harboring the variant allele divided by all reads covering to
that base, of exome and validation sequencingwere highly correlated
(Pearson correlation = 0.93) (Supplemental Fig. 4).
Copy number and LOH analysis
For cohort II, Affymetrix SNP 6.0 arrays were preprocessed
by either aroma.affymetrix (Bengtsson et al. 2009) or Copy-
NumberInferencePipeline in GenePattern (http://genepattern.
broadinstitute.org) and segmented by the circular binary seg-
mentation algorithm (Olshen et al. 2004). Tumor and matched
normal samples were used in pairs to obtain somatic alterations.
The GISTIC2 algorithm (Mermel et al. 2011) was applied to the
segmented copy number profiles for significant aberrations
and sample-specific events. For cohort I, GISTIC2 outputs were
downloaded from the Broad GDAC Firehose website (https://
confluence.broadinstitute.org/display/GDAC/Home). In both co-
horts I and II, the loss of heterozygosity (LOH) levels were de-
termined by the paired parent-specific circular binary segmentation
method (PSCBS, v0.28.1) (Olshen et al. 2011) to raw Affymetrix
SNP 6.0 CEL files from paired tumor and normal samples.
Inference of cellular frequency distributions of sSNVs
We defined cellular frequency of a mutation as the fraction of cells
harboring the mutation. To estimate cellular frequency in in-
dividual tumors, we integrated reference and variant allele counts,
LOH, and copy number alterations using the PyClone algorithm
(version 0.2) (Shah et al. 2012). In brief, PyClone implements
a Dirichlet process clustering model that simultaneously estimates
the distribution of the cellular frequency for each mutation. Copy
number levels at somatic mutation sites were inferred by thresh-
olded copy number profiles determined by GISTIC 2.0 on a single
sample basis. We considered ‘‘2’’ as homozygous deletion, ‘‘1’’
as hemizygous deletion, ‘‘0’’ as copy number neutral, ‘‘1’’ as low
level gain, and ‘‘2’’ as high level gain. LOH status was inferred from
the PSCBS LOH file. PyClonewas performed using default settings.
The outputs were a pairwise mutation co-occurrence matrix and
cellular frequency value distribution per sSNV estimated from
Markov-chain Monte Carlo (MCMC) sampling. The median value
of the MCMC sampling-derived distribution was used as a repre-
sentative cellular frequency for each mutation.
Inferring cancer cell fraction and clonal status of sSNVs
When corrected for tumor cell content, the cellular frequency of
each mutation can be used to infer the cancer cell fraction of the
mutation. We assumed a group of mutations were shared by all
cancer cells in a biopsy, and their cellular frequencies reflected the
relative abundance of cancer cells (cellularity) in the admixture of
infiltrating normal cells. Then, the cancer cell abundance in each
sample can be used as a scale factor for rescaling cellular frequencies
to the cancer cell fractions of the mutations in the sample. To infer
cancer cell abundance, we performed hierarchical clustering of
the pairwise mutation co-occurrence matrix and then selected
a group of at least 10 mutations with the highest median cellular
frequency at a given tree cutoff threshold. Multiple grouping
thresholds were applied, andwemanually inspected the results to
select the most reasonable one. Euclidean distances were used in
hierarchical clustering. The distribution of rescaled cancer cell
fraction per mutation in a tumor was used to compute the clonal
probability of the mutation.We defined amutation to be clonal if
the probability of the mutation being present in >95% of the
cancer cells was more than 0.5, or subclonal otherwise. The cutoff
of 0.5 was selected based on the empirical distribution of clonal
probabilities for our data set.
Tumor purity estimation
In cohort II, tumor purities and ploidy were estimated by the
ASCAT algorithm (v 2.1) using Affymetrix SNP 6.0 array data (Van
Loo et al. 2010).
Survival analysis
We carried out a survival analysis using the ‘‘Survival’’ package in R
version 3.1.0 (R Core Team 2014). Clinical information for cohort I
was downloaded from TCGA data portal (Brennan et al. 2013). An
event was considered to be either disease progression or death.
Survival curves were estimated by the Kaplan-Meier method. The
statistical significance of survival differences was calculated using
the log-rank test in the ‘‘Survival’’ package.
Statistical analysis
All statistical analysis was performed with R version 3.0.1 (R Core
Team 2014).
Data access
SNP6 array and sequencing data from this study have been sub-
mitted to the European Genome-phenome Archive (EGA; http://
www.ebi.ac.uk/ega/) under accession number EGAS00001001033.
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